Diagnostics

As new treatments for degenerative eye disease emerge, OpZira's hiring of a key innovator from its past signals a major push into AI-driven diagnostics.

With stringent NYS approval secured, Fellow Health’s mail-in semen analysis enters a key market, signaling a major shift in at-home diagnostics and male reproductive care.

Landmark 2-year study shows an AI diagnostic for diabetic kidney disease actively improves patient outcomes, validating a new era of precision medicine.

For patients with inoperable brain tumors, new diagnostic guidelines offer hope by validating CSF profiling, a disruptive technology poised to redefine care.

GRAIL's revolutionary cancer test failed a key trial, wiping out billions and sparking a fraud lawsuit. A deep dive into the fallout for investors and science.

GuideAI Health's new AI platform just hit the public market. It promises to find hidden vascular disease in routine scans, but can it navigate the risks?

A new blood test and a powerful partnership between a diagnostics firm and a patient foundation aim to end years of misdiagnosis for a rare lung disease.

A new partnership brings advanced, FDA-cleared HPV testing to the home. The true innovation, however, is the system built to overcome the last-mile problem.

Co-Dx's local-first strategy empowers communities against disease, but can this innovative public health play overcome the company's financial headwinds?

As Abbott prepares its July 16th earnings report, all eyes are on more than just the balance sheet. It's a test of its post-acquisition strategy.

Carolyn Starrett's appointment to the NeoGenomics board signals a major push to integrate AI and real-world data into the core of cancer diagnostics.

Aidoc's 'First Read' AI has earned a coveted FDA Breakthrough designation, promising to ease radiologist workload. But can an algorithm be trusted with your health?

With a focus on AI, deepfake detection, and core infrastructure, the latest Sanabil Accelerator cohort reveals a strategic bet on regional resilience and global scale.

A new ARPA-H grant aims to replace 50-year-old tech with a rapid blood test for fetal hypoxia, a move that could slash C-sections and save lives.

A new animal-free ingredient from Proliant Health & Biologicals aims to solve major regulatory, ethical, and performance challenges in the life sciences.

S&G Labs just launched a veteran scholarship. It’s more than PR—it’s a blueprint for how mission-driven companies are redefining impact in 2026.

Facing delisting, Virax Biolabs consolidates its shares in a bid to survive. This move buys time, but the real test lies in its innovative T-cell technology.

A groundbreaking study in Nature Water reveals wastewater analysis can detect fentanyl trends 15 months ahead of traditional data, offering a powerful new tool.

Following a $30M funding round, Mammogen appoints Dr. Elise Berman as CMO to spearhead its genTRU-breast™ test, aiming to solve the dense breast dilemma.

The Brain Aneurysm Foundation partners with a tech advocacy group to highlight AI's life-saving potential in spotting deadly aneurysms before they rupture.